PT3413897T - Métodos de tratamento e profilaxia do vih e sida - Google Patents

Métodos de tratamento e profilaxia do vih e sida

Info

Publication number
PT3413897T
PT3413897T PT177061025T PT17706102T PT3413897T PT 3413897 T PT3413897 T PT 3413897T PT 177061025 T PT177061025 T PT 177061025T PT 17706102 T PT17706102 T PT 17706102T PT 3413897 T PT3413897 T PT 3413897T
Authority
PT
Portugal
Prior art keywords
hiv
aids
treatment
prophylaxis methods
prophylaxis
Prior art date
Application number
PT177061025T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PT3413897T publication Critical patent/PT3413897T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
PT177061025T 2016-02-12 2017-02-10 Métodos de tratamento e profilaxia do vih e sida PT3413897T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19

Publications (1)

Publication Number Publication Date
PT3413897T true PT3413897T (pt) 2023-08-28

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177061025T PT3413897T (pt) 2016-02-12 2017-02-10 Métodos de tratamento e profilaxia do vih e sida

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20250136420A (enExample)
CN (2) CN108697727A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TWI822652B (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
US12227536B2 (en) * 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
PH12021500034A1 (en) * 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
JP7700096B2 (ja) 2019-07-27 2025-06-30 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
PL219609B1 (pl) 2003-02-19 2015-06-30 Masanori Baba Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
AU2020328518A1 (en) * 2019-08-13 2022-03-10 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
HRP20230935T1 (hr) 2023-11-24
US20200101098A1 (en) 2020-04-02
JP2022062170A (ja) 2022-04-19
HUE063532T2 (hu) 2024-01-28
CN108697727A (zh) 2018-10-23
MX2018009763A (es) 2018-11-29
SV2018005733A (es) 2018-12-14
PL3413897T3 (pl) 2023-10-02
JP6810972B2 (ja) 2021-01-13
HK1257347A1 (en) 2019-10-18
JOP20170038B1 (ar) 2021-08-17
KR102317570B1 (ko) 2021-10-25
JP7021314B2 (ja) 2022-02-16
LT3413897T (lt) 2023-08-25
US10537589B2 (en) 2020-01-21
KR20250136420A (ko) 2025-09-16
AU2020202866A1 (en) 2020-05-21
AU2017217656A1 (en) 2018-08-23
ZA201805073B (en) 2019-05-29
RS64448B1 (sr) 2023-09-29
US20250073254A1 (en) 2025-03-06
PH12018501712A1 (en) 2019-05-15
US20220331350A1 (en) 2022-10-20
US11337991B2 (en) 2022-05-24
CA3013473C (en) 2021-10-26
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
AU2020202866B2 (en) 2022-04-07
NZ784982A (en) 2025-03-28
EP3413897B1 (en) 2023-06-14
KR20220126787A (ko) 2022-09-16
JP7559175B6 (ja) 2024-10-22
FI3413897T3 (fi) 2023-08-25
DOP2018000183A (es) 2018-12-31
JP2021001189A (ja) 2021-01-07
AU2022201686B2 (en) 2024-08-08
SI3413897T1 (sl) 2023-11-30
DK3413897T3 (da) 2023-09-18
CL2018002150A1 (es) 2018-12-14
MX2022002925A (es) 2023-02-10
IL260874A (enExample) 2018-09-20
MX390604B (es) 2025-03-20
MD3413897T2 (ro) 2023-11-30
EA201891814A1 (ru) 2019-01-31
BR112018016349A2 (pt) 2018-12-26
US20180055867A1 (en) 2018-03-01
MY197090A (en) 2023-05-24
UA126375C2 (uk) 2022-09-28
US12171776B2 (en) 2024-12-24
JP2019504857A (ja) 2019-02-21
JP2024001206A (ja) 2024-01-09
CN113509480A (zh) 2021-10-19
JP7559175B2 (ja) 2024-10-01
NZ745065A (en) 2023-11-24
GEP20217231B (en) 2021-03-25
EP3413897A1 (en) 2018-12-19
TN2018000267A1 (en) 2020-01-16
AU2022201686A1 (en) 2022-03-31
ES2953535T3 (es) 2023-11-14
KR20210049201A (ko) 2021-05-04
CA3013473A1 (en) 2017-08-17
TWI822652B (zh) 2023-11-21
KR20180108815A (ko) 2018-10-04
MX2022002924A (es) 2022-12-15
TW201731514A (zh) 2017-09-16
SG11201806783WA (en) 2018-09-27
TW202417010A (zh) 2024-05-01
IL260874B2 (en) 2023-10-01
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
PT3413897T (pt) Métodos de tratamento e profilaxia do vih e sida
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
EP3565371A4 (en) SESSION PROCESSING METHOD AND DEVICE
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
HRP20181130T1 (hr) Postupci za liječenje infekcija virusom filoviridae
HUE052104T2 (hu) Eszközök és eljárások HBV kezelésére
IL273932A (en) Methods of treatment and prevention of viral infection
EP3160475C0 (en) NUCLEOSIDES AND SUBSTITUTED NUCLEOTIDES FOR TREATING INFECTIONS DUE TO FILOVIRIDAE
HRP20181941T1 (hr) Alat za njegu i postupak
EP3519833A4 (en) PROCEDURE FOR PROGNOSIS AND TREATMENT
SG11201609652RA (en) Treatment of polybacterials infections
SG10201913559VA (en) Methods for treating and preventing c. difficile infection
EP3915472C0 (en) DEVICE FOR TREATING VAGINAL ATROPHY
PT3265087T (pt) Método de tratamento com tradipitant
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
BR112018000204A2 (pt) métodos de tratamento de colite
EP3657744A4 (en) Message processing
EP3522865A4 (en) METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
EP3431517A4 (en) Copolymer and surface treatment
DK3302478T3 (da) Pac-1 kombinations behandling
IL291266A (en) Preparations and methods for treating infections
IL271987A (en) Regimens for the treatment of HIV infections and AIDS
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT